

FOR IMMEDIATE RELEASE – October 30, 2008

Contacts:

Steven R. Smith
Vice President, Business Development
Dow Pharmaceutical Sciences, Inc.
Petaluma, California
707-665-4672
ssmith@dowpharmsci.com

DOW PHARMACEUTICAL SCIENCES, INC. TO PRESENT SCIENTIFIC POSTER AT AAPS EVALUATING THE AFFECT OF FLOW RATE, TISSUE THICKNESS AND RECEPTOR PHASE TYPE ON DRUG PENETRATION WHEN APPIED TOPICALLY TO HUMAN DERMATOMED AND DERMIS ONLY SKIN

Determining the most important factors for successful *in vitro* skin permeation studies

PETALUMA, CA, Dow Pharmaceutical Sciences, Inc., the leading provider of topical formulation development services for prescription products, will present a new poster – “*Characterization of Potential Percutaneous Absorption and Penetration Differences of Human Dermatomed Skin and Dermis-Only with Various Receptor Phase Flow Rates, In Vitro, using (³H)-Clotrimazole and (³H)-Hydrocortisone as Model Compounds*” at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Atlanta, Georgia, November 17th-19th.

“These experimental findings help substantiate the factors most critical to the success of *in vitro* permeation studies.”, said Dr. Daniel Bucks, Dow’s Director of Skin Biology and Drug Delivery, “Utilizing our Bronaugh Flow-Through Diffusion Cell Systems and two model compounds, we were able to evaluate the effect of human skin with an intact stratum corneum as well as isolated human dermis, receptor phase compositions and receptor fluid flow rate on skin penetration.”

Copies of the poster will be available at Dow’s exhibit in booth #925. Dow also will be displaying its new corporate video throughout the meeting.

Dow Pharmaceutical Sciences, Inc. www.dowpharmsci.com, located in Petaluma California, 40 miles North of San Francisco, has focused on semisolid and solution

dosage forms since 1977 and has developed more topical prescription formulations than any other company in the world. Clients gain access to Dow's 32 years of experience focused on topical product development. During 2005-2007, the FDA approved 22 topical product NDAs. Nine of these (40%) were formulated at Dow.

Contacts:

Dow Pharmaceutical Sciences, Inc.
Steven R. Smith, 707-665-4672
Vice President, Business Development
ssmith@dowpharmsci.com